NASDAQ:PHIO Phio Pharmaceuticals Q3 2026 Earnings Results & Report $0.83 -0.01 (-0.70%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Phio Pharmaceuticals met analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.36 versus the -$0.36 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call7:00 AM ET Phio Pharmaceuticals EPS ResultsActual EPS-$0.36Consensus EPS -$0.36Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersPhio Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Phio Pharmaceuticals Q3 2026 Earnings FAQ Did Phio Pharmaceuticals beat earnings estimates for Q3 2026? Phio Pharmaceuticals (NASDAQ:PHIO) reported earnings of -$0.36 per share for Q3 2026, matching the consensus estimate of -$0.36. The report was announced on Thursday, November 5, 2026. Phio Pharmaceuticals Earnings HeadlinesPhio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual MeetingNovember 9 at 8:10 AM | theglobeandmail.comPhio Pharmaceuticals Reports Q3 2026 Results and Business Update, Advances PH-762 Toward Phase 2b InitiationNovember 8 at 2:35 PM | markets.businessinsider.comWhy Iran May Only Be the First MoveTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.November 10 at 1:00 AM | Behind the Markets (Ad)Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMPhio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study InitiationNovember 6, 2026 | insidermonkey.comPhio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug SubstanceOctober 13, 2026 | finance.yahoo.comSee More Phio Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email. Email Address About Phio PharmaceuticalsPhio Pharmaceuticals (NASDAQ:PHIO) (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle. The company has developed investigational product candidates targeting pathways such as PD-1 and STAT3, including PH-762 and PH-894, for potential use in solid tumors and other oncology applications. The company was formerly known as RXi Pharmaceuticals and adopted the name Phio Pharmaceuticals in 2018. Based in Marlborough, Massachusetts, Phio is a clinical-stage company whose product candidates remain investigational and are subject to clinical development and regulatory review. Its publicly disclosed activities have primarily centered on advancing its INTASYL-based oncology pipeline.View Phio Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
